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In this review we discuss the clinical manifestations,
pathogenesis, and treatment of hepatitis C virus
(HCV)–related cryoglobulinemia. HCV is a major cause of liver-
related morbidity and is increasingly recognized as an
instigator of B-cell lymphoproliferative disorders such as
mixed cryoglobulinemia and non-Hodgkin lymphoma.
Cryoglobulinemia is characterized by the clonal expansion of
rheumatoid factor–expressing B cells in the liver, lymph
nodes, and peripheral blood, resulting in the presence of
cryoglobulins in the circulation. Cryoglobulins are cold-
insoluble immune complexes containing rheumatoid factor,
polyclonal IgG, and HCV RNA that precipitate and deposit on
vascular endothelium, causing vasculitis in organs such as
the skin, kidneys, and peripheral nerves. A subset of patients
develops a low-grade lymphoma composed of B cells that are
immunophenotypically similar to the expanded B cells seen
in cryoglobulinemia. HCV-related B-cell lymphoproliferative
disorders likely comprise a spectrum of disease, ranging from
asymptomatic clonal B-cell expansions to pathogenic
cryoglobulinemia and lymphoma. It is unclear how B cells
become dysregulated during the course of chronic HCV
infection, and continued patient-centered research is
necessary to elucidate the pathogenesis of HCV-related
B-cell dysregulation.
Kidney International (2009) 76, 818–824; doi:10.1038/ki.2009.247;
published online 15 July 2009
KEYWORDS: B cells; cryoglobulinemia; HCV; lymphoma; rheumatoid factor;
vasculitis
Hepatitis C virus (HCV) chronically infects over 170 million
people worldwide, and is the leading indication for liver
transplantation in the United States and Europe. HCV is a
positive-strand RNA virus with a 9.6-kb genome that
replicates predominantly in the liver. HCV frequently causes
extrahepatic manifestations, the most common and severe of
which is mixed cryoglobulinemia (MC), a systemic vasculitis
affecting small- and medium-sized arteries and veins. MC is
characterized by the deposition of immune complexes
containing rheumatoid factor (RF), IgG, HCV RNA, and
complement on endothelial surfaces, eliciting vascular
inflammation through poorly understood mechanisms. It is
clear, however, that HCV MC is a B cell lymphoproliferative
disorder. It is unknown how B cells activate, clonally expand,
and differentiate to produce pathologic quantities of self-
reactive RF during chronic HCV infection.
CLASSIFICATION AND SEROLOGICAL DETECTION OF
CRYOGLOBULINEMIA
In 1966, Meltzer1 described MC as the clinical triad of
palpable purpura, arthralgia, and asthenia accompanied by
organ involvement (e.g., nephropathy and neuropathy) and
elevated serum RF, defined as Ig capable of binding IgG. It is
now known that this triad is rare; many MC patients are
asymptomatic, and the most common clinical manifestation
is palpable purpura, which is often transient. Cryoglobulins
are classified as type I (monoclonal Ig only), type II (mixture
of monoclonal Ig, which is usually IgM RF and polyclonal
IgG), and type III (mixture of polyclonal Ig that is usually
IgM and polyclonal IgG).2 ‘Essential’ MC refers to the subset
of MC patients for whom no cause has been identified; since
the identification of HCV in 1989, it has been recognized as
the cause of 490% of MC, and o5% of cases are now
considered ‘essential’.3–5 HCV is primarily associated with
type II MC (which typically has an IgMk RF with anti-
idiotypic activity6), and to a lesser extent, with type III MC.
Type I MC is rarely seen in HCV. Serum RF, which is elevated
in 16–70% of HCVþ patients,7,8 is usually increased in the
setting of HCV MC, and the levels of complement,
particularly C4, may be profoundly decreased. Non-HCV
causes of MC include infectious agents (e.g., human
immunodeficiency virus and hepatitis B virus) and auto-
immune disorders (e.g., systemic lupus erythematosus,
Sjo¨gren syndrome, and systemic sclerosis).9 A shared feature
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of these disorders is chronic inflammation in the setting of
high antigenic load, suggesting that antigen-driven B cell
dysregulation is a prerequisite for the development of MC.
Serological testing for cryoglobulins is straightforward,
but serum preparation must be performed at 371C to prevent
premature immune complex precipitation. Serum is stored at
41C for 7 days, inspected daily for a precipitate, and spun in a
Wintrobe tube for calculation of cryocrit, the percentage of
cryoglobulin in the serum. A cryocrit X2% is positive. The
cryocrit is then typed using immunofixation.9 Some chronic
HCV patients with MC may be HCV Abþ , yet have
undetectable plasma HCV RNA.10 In such cases, examination
of the cryoprecipitate for HCV RNA is warranted.
EPIDEMIOLOGY OF HCV-RELATED MC
Estimates of MC prevalence in HCV infection vary widely,
ranging from 10 to 70%; many of these differences may be
due to population selection and lead-time biases. In addition,
the clinical assessment of MC is not standardized, and the
laboratory test for MC is prone to false negative results. MC
is associated with increased duration of HCV infection;
HCVþMCþ patients have an apparent duration of HCV
infection that is almost twice as long as in HCVþMC
patients,11 and an Italian HCVþ population was found to
have a yearly incidence rate of 3%.12 It is controversial
whether MC is an independent risk factor for the develop-
ment of cirrhosis. It was reported early on that MC was a risk
factor for cirrhosis (reviewed in Agnello V6), and a meta-
analysis of studies predominantly carried out in areas where
440% of HCVþ individuals have MC showed MC to confer
an OR of 4.87 for cirrhosis, independent of age, gender, and
estimated duration of HCV infection.13 All HCV genotypes
have been found in HCV MC, and there is no clear
association with a particular genotype. Female gender may
predispose toward MC, although this association is not
strong.8,14
Mixed cryoglobulinemia is more prevalent in Southern
Europe than in Northern Europe and North America; up to
60% of HCV-infected individuals in Southern Europe have
MC,13 whereas the prevalence among HCVþ patients in the
United States (where no ethnic bias for MC has been
reported) is considerably lower (10–50%),15 and the pre-
valence of symptomatic MC is much lower. It is unclear
whether this difference is due to unidentified genetic factors.
Although genome-wide association scans have not been
performed, several groups have focused on HLA alleles. These
studies are limited by their small sample sizes, and
comparisons among studies are complicated by varying
HLA typing methods and different geographical populations
with dissimilar HLA frequencies. Nevertheless, several studies
conducted primarily in Italy, France, and China have
associated DRB1*11 alleles and DR3, DR5, and DR6
serological clusters with MC.16–21 However, a group in Japan
failed to detect any significant associations between HLA and
HCV MC.22
CLINICAL MANIFESTATIONS
Cryoglobulinemic vasculitis
HCV MC vasculitis primarily affects the small- and medium-
sized vessels of the skin, kidneys, and peripheral nerves.
Histology typically reveals a leukocytoclastic vasculitis, with
deposition of IgM RF, IgG, C3, and neutrophils in the vessel
wall. A necrotizing vasculitis, with fibrinoid necrosis of the
intima and the inflammation of the entire vessel wall and
perivascular space, may also occur. Palpable purpura
(Figure 1a), primarily of the lower legs, occurs in more than
90% of patients with symptomatic HCV MC, is frequently
intermittent, and is often the initial manifestation of
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Figure 1 |Cutaneous manifestations and typical B-cell immunophenotype of HCV MC. Palpable purpura in a patient with hepatitis C
virus (HCV) vasculitis (a). This patient has a marked clonal expansion of rheumatoid factor (RF) WA–bearing IgMþkþCD27þCD21low
peripheral B cells (b).
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HCV MC.5 These purpuric lesions may occasionally progress
to chronic ulcers and frank gangrene. HCV MC renal
involvement is usually Type I membranoproliferative glo-
merulonephritis,23 and it frequently heralds a poor clinical
course. Manifestations range from isolated proteinuria to
nephritic syndrome with variable progression toward chronic
renal insufficiency. The membranoproliferative glomerulone-
phritis is characterized by endocapillary mesangial-cell
proliferation, monocytic infiltration, double contour mem-
branes, glomerular IgM, IgG and C3 deposition, eosinophilic
PAS-positive intraluminal deposits, and vasculitis of the
small- and medium-sized renal arteries.24,25 The incidence of
neurological involvement is variable. Sensorimotor neuro-
pathy arises from cryoglobulin deposition in the vasa
vasorum. Painful paresthesias and concomitant weakness
particularly in the lower limbs may occur,26 as may isolated
mononeuritis, manifested by foot or wrist drop.
HCV-related lymphoproliferation
Since the identification of HCV, many reports have linked
HCV infection to the development of B cell non-Hodgkin
lymphoma (NHL).27 However, given the low incidence of
NHL during HCV infection, it has been difficult to ascertain
the additive risk HCV confers for NHL. A large retrospective
trial conducted among the US veterans has recently
confirmed that HCV is associated with NHL, as well as
with other B-cell lymphoproliferative disorders such as
Waldenstro¨m macroglobulinemia and monoclonal gammo-
pathy of unknown significance.15 It is likely that HCV MC
represents an antigen-driven, relatively benign clonal B cell
lymphoproliferation that, with continued antigenic
stimulation, occasionally progresses toward overt NHL.
Pre-malignant B cell clones can be detected in the bone
marrow or in the liver several years before the development of
frank lymphoma.28 Typically, the NHL that arises in HCVþ
MCþ patients is low-grade and is characterized by clonal
RFþ B cells that may be present in the liver, spleen,
peripheral lymph nodes, peripheral blood, and/or bone
marrow. It has been proposed that a subset of these low-grade
NHL evolves to a high-malignancy phenotype. The most
frequent NHL histiotypes are immunocytoma, splenic
marginal zone lymphoma, MALT (mucosa-associated lym-
phoid tissue) lymphoma, and aggressive diffuse large B cell
lymphoma,29–31 suggestive of the expansion of a germinal
center or post-germinal center B cell during or after antigenic
stimulation. It has been reported that higher-grade diffuse
large B cell lymphoma is predominantly associated with
MC, rather than MCþ , HCV infection.32 It is possible that
a fundamentally different etiological mechanism underlies
the development of aggressive NHL in the absence of MC.
Consistent with the hypothesis that continued antigenic
presence is required for ongoing clonal B cell proliferation,
eradication of HCV can lead to disappearance of the
associated low-grade NHL,33 similar to what has been
observed with H. pylori-induced MALT lymphomas. An
aggressive subset of H. pylori MALT contains t(11;18)
translocations and does not regress after H. pylori eradica-
tion. In contrast, there is no convincing evidence that
chromosomal translocations are frequent in HCV-related
NHL. Although several groups have detected t(14:18) in
peripheral blood mononuclear cells from HCVþMCþ
patients,34–36 these translocations have been identified in
healthy controls37 as well as in HCV NHL patients.38
Pathogenesis of HCV-induced B-cell lymphoproliferation
HCV MC is characterized by aberrant RFþ B-cell lympho-
proliferation (Figure 1b). Multiple groups have shown that
clonal B cell expansions are present in the liver and peripheral
blood of HCVþMCþ patients.39–42 We have shown that
these B cells express memory markers and are markedly
biased toward the RF WA-encoding VH1-69, JH4, and Vk3-20
gene segments,41 which are also preferentially expressed in
HCV-related NHL.43,44 It is unclear why such an expansion
occurs more readily in chronic HCV infection than in other
chronic viral diseases such as hepatitis B virus or human
immunodeficiency virus. Increased serum B cell-activating
factor, a TNF-a family member required for B cell survival,
has been reported in systemic lupus erythematosus, rheu-
matoid arthritis, and Sjo¨gren syndrome. B cell-activating
factor inhibits B-cell apoptosis, and high levels may allow the
survival of autoreactive B cells. Elevated B cell-activating
factor has been described in HCV MC,45–48 although the
underlying mechanism remains unclear. Interestingly, B cell-
activating factor promoter polymorphisms may predispose to
MC,49 but further studies are needed to confirm this
association.
It has been proposed that HCV infects B cells, leading to
direct malignant transformation. However, this model fails to
explain the RF restriction seen in HCV MC, unless it is
presumed that HCV preferentially infects RFþ B cells.
Nevertheless, a B cell line that productively releases infectious
HCV has been reported,50 and several groups have claimed to
detect minus-strand RNA, the replicative intermediate,
associated with lymphocytes from HCVþ patients;51–53
however, it has been shown that artifactual detection may
occur, possibly through non-specific priming events.54 One
group has failed to detect HCV infection in malignant B
cells,55 and we have shown that B cells lack necessary HCV
entry receptors and cannot support HCV replication,56 but
can associate with low levels of HCV RNA. Furthermore,
when HCV MC patients are treated with rituximab, serum
HCV RNA levels often increase, arguing against a potential B
cell reservoir of HCV infection. Taken together, cumulative
data suggest that HCV viral particles may be bound directly
or indirectly to B cells, but HCV rarely infects B cells.
It has alternatively been postulated that specific HCV
proteins are necessary for clonal B cell expansion. The
suggested IgG Fc-binding activity of HCV core57 could
possibly lead to enhanced HCV-immune complex generation.
Moreover, NS5A protein may sequester p53 and predispose
cells toward proliferation;58 however, as NS5A expression
requires active replication, this scenario necessitates B cell
820 Kidney International (2009) 76, 818–824
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infection. High concentrations of HCV E2 protein in vitro
polyclonally stimulate B cell expansion through interactions
with CD81, a known HCV E2 entry factor.59 It has also been
claimed that HCV E2-CD81 interactions trigger activation-
induced cytidine deaminase expression, resulting in stochas-
tic immunoglobulin hypermutation.60 Neither of these
scenarios explains the clonal RFþ B cell expansion seen in
HCVþ MCþ patients. However, the BCR cloned from an
HCV-associated NHL was shown to bind HCV E2, and it was
hypothesized that simultaneous engagement of the BCR and
CD81 could result in a reduced B cell stimulation threshold.61
Intriguingly, a potent HCV-neutralizing mAb cloned from an
asymptomatic HCVþ patient is coded for by VH1-69/JH4
gene segments that also encode RF WA.62,63 It is unlikely that
this mAb has RF activity, as it is extensively hypermutated
and utilizes a Vk4-1 light chain. Another group has reported
that a minority of HCV MC patients’ IgM RF crossreacts
with IgG Fc and HCV NS3, and they speculate that RF
activity is generated during the normal adaptive immune
response to HCV.64
We propose that IgG-bound HCV specifically drives the
clonal expansion of RFþ B cells (Figure 2). During chronic
HCV infection, immune-complexed HCV stimulates the
expansion of VH1-69
þ B cells, which on continued antigenic
exposure (usually over several years) become clonally
predominant. We postulate that these cells have expanded
independently of T cell help in response to dual ligation of
BCR and toll-like receptor 7 by IgG and HCV RNA,
respectively. We have found that the clonal RFþ memory B
cells have low levels of somatic hypermutation, likely
acquired in response to antigenic exposure, and that they
have downregulated CD21, the complement 3d receptor,
which together with CD19 and CD81 forms the B cell co-
receptor complex.41 We propose that these cells, although
activated and clonally expanded, may have dampened
responses to antigenic stimulation. This self-attenuation
process, although incomplete in HCV MC, might mitigate
otherwise unchecked activation and proliferation pathways,
and serve to maintain overall clonal B cell numbers at a
relatively stable, albeit elevated, steady state level. We are
actively investigating requirements for B cell survival,
stimulation, and differentiation in HCV MC patients.
TREATMENT
Consistent with HCV MC being an antigen-stimulated
process, the most effective treatment for HCV MC is
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Figure 2 |Proposed mechanism of clonal B cell expansion in hepatitis C virus (HCV)–induced cryoglobulinemia. Immunoglobulins,
complement, and HCV viral particles are not drawn to scale. BAFF, B cell-activating factor; NHL, non-Hodgkin lymphoma.
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eradication of the underlying HCV infection. MC symptoms
and evidence of B cell lymphoproliferative disorder almost
always disappear in sustained virological responders,
although persistence has been rarely described.65,66 This
persistence may be reflective of continued HCV replication
below the limit of detection, or long-term persistence of viral
antigen in the absence of replicating virus. Purpuric rash
resolves more frequently than glomerulonephritis or neuro-
pathy.67–70 HCV RNA relapse is associated with recurrence of
MC and clinical symptoms. The current standard of care for
HCV infection is pegylated interferon-a-2a/2b (pIFN) in
combination with ribavirin (RBV), which results in a
sustained virological response rate of 45–50% in genotypes
1 and 4, and 70–80% in genotypes 2 and 3 in HCV-
monoinfected patients. Small pilot studies show that pIFN/
RBV is effective in treating HCV in MCþ patients.
Importantly, eradication of HCV with IFN/RBV leads to
resolution of HCV MC-associated splenic villous lymphomas
and immunocytomas.33,71,72
Treatment with antivirals must be individualized, as RBV is
contraindicated in individuals with creatinine clearanceo50ml/
min, pIFN/RBV is poorly tolerated in ESRD, even with weekly
plasma monitoring,73 and pIFN is contraindicated in renal
allograft recipients. For patients unable to tolerate antivirals, or
for those with severe renal disease, or for those who have failed
to reach sustained virological response after antiviral therapy,
symptomatic treatment of vasculitis with plasmapheresis,
rituximab, or prednisone should be considered.74
Rituximab is a chimeric monoclonal antibody that binds
to the pan B cell marker, CD20, and effects B cell destruction
through complement-dependent and antibody-mediated
cellular cytotoxicity.75 Following a standard course of
375mg/m2/week 4 weeks, B cells are typically undetectable
in the periphery, and take 6–18 months to recover. Several
small studies have shown that 80–93% of patients with HCV
MC vasculitis respond to rituximab,76 and the reduction of
peripheral VH1-69
þ memory B cells persists 12 months after
treatment.77 Symptoms usually reappear with reconstitution
of peripheral B cells. Although rituximab is generally safe and
well tolerated,74 its use has been associated with modestly
elevated (up to two-fold) levels of HCV viremia,78 pre-
sumably due to the reduction of partially protective humoral
control.79 The safety and efficacy of multiple courses of
rituximab in the setting of HCV MC are unknown. Studies
are needed to determine the optimum duration, dosage, and
readministration of rituximab in HCV MC.
Prednisone 1–1.5mg/kg/day has successfully been used to
treat vasculitic symptoms. However, systemic corticosteroids
are not curative, have significant side effects, and may lead to
increases in HCV viral load. There are extremely limited data
on the palliative use of plasmapheresis to treat HCV MC
vasculitic symptoms. However, case reports suggest that it is
safe, and may result in improvement in glomerulonephritis,80
neuropathy,81 and purpura.82,83 Importantly, randomized
controlled trials are needed to determine the appropriate use
of these alternative therapies for HCV MC.
CONCLUSION
Hepatitis C virus cryoglobulins contain RF, polyclonal IgG, and
HCV RNA that precipitate and deposit on vascular endothe-
lium, causing an end organ vasculitis. Patients often have
striking clonal expansions of RF-bearing IgMþkþCD21low
memory B cells with restricted usage of RF-encoding Ig gene
segments. Most of these activated B cells have low-to-moderate
levels of somatic hypermutations, suggestive of a response to
antigenic stimulation. A smaller subset of patients with MC
develop a low-grade NHL comprised of B cells that are
immunophenotypically similar to the expanded B cells seen in
MC. The antigenic dependence of these B cells is supported by
evidence that HCV-related MC and NHL disappear after
successful treatment of HCV infection. However, the mechan-
isms leading to B cell activation and expansion are unknown. It
has been hypothesized that immune complexes of IgG-bound
HCV stimulate RF-expressing B cells through the B cell
receptor and act in concert with undefined accessory
molecules. Continued patient-centered studies are necessary
to elucidate the pathogenesis of HCV MC and to devise
improved therapeutic strategies for affected patients.
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